MAPK1 and neoplasm: Ras/ERK hyperactivation is a common feature of a variety of tumor types featuring activating KRAS, NRAS, or BRAF gene mutations [7]; however, mutations in the pathway are detected in only ~3.2% of all breast lesions [8].